Global pharmaceutical company Clinigen has extended its clinical trial supply agreement with Accord Healthcare through its Clinical Trial Service (CTS) business.
clinical trials
The two pharma companies have been partnered since 2012 to deliver oncology injectable products into clinical trials. Now, the extended partnership will include Accord’s European solid dose products, including those in the central nervous system, autoimmune, diabetes and anti-viral therapy areas. A first for the industry, Clinigen is also offering pharma companies an ‘on-demand’ service to Accord’s products.
Any Clinigen client running clinical trials will have access to the ‘on-demand’ service and will also be offered instant access to products from Accord’s generic oncology injectables portfolio. According to the companies, this is the first type of service to provide instant access to products solely for clinical trials in the industry. It has been designed to tackle the constant timeline and flexibility challenges that occur during clinical trials.
Shaun Chilton, group chief executive officer of Clinigen, said: “This extended agreement builds on the strong partnership we have with Accord in providing access to its medicines for use in clinical trials. The launch of our ‘on demand’ offering demonstrates the ability we have across the Group and the specialisms we have in the supply and distribution of medicines. These capabilities enable us to provide the best possible service to those running clinical trials.”
Phill Semmens, senior vice president commercial, Accord Healthcare, EMENA, said: “We are delighted that the strong collaboration Accord and Clinigen have built over the past six years continues to expand with the agreement to include solid dose oral products. The scope of this partnership is a first for the industry, allowing us to ensure that our products are available as comparators in a variety of vital clinical trials, helping to further medical knowledge and the identification of new treatment options to improve patient care.”